A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

NCT06115642 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Malignant Solid Tumors

Interventions

DRUG: HLX43
DRUG: HLX10

Sponsor

Shanghai Henlius Biotech